Clinical Trials in Los Angeles

Showing 241-260 of 8,055 trials

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

NCT03749187

This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma.

GlioblastomaIDH1 Gene MutationIDH2 Gene Mutation+7 more

University of California, San Francisco78 participantsStarted Apr 2019

Los Angeles, California, United States • San Francisco, California, United States • New Haven, Connecticut, United States +8 more locations

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2< 1 mile

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

NCT05488314

The purpose of this study is to identify the recommended Phase 2 combination dose (RP2CD\[s\]) of the amivantamab and capmatinib combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection), and to evaluate the antitumor effect of the amivantamab and capmatinib combination therapy in mesenchymal-epithelial transition (MET) exon 14 skipping mutation and MET amplified NSCLC, when administered at the selected RP2CD(s) in Phase 2 (expansion).

Carcinoma, Non-Small-Cell Lung

Janssen Research & Development, LLC57 participantsStarted Dec 2022

Birmingham, Alabama, United States • Cerritos, California, United States • Los Angeles, California, United States +75 more locations

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

Find Trials by Condition in Los Angeles

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

An Exosomal miRNA-based Liquid Biopsy for ICC Detection

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

Terumo Aortic Global Endovascular Registry

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy